Results 51 to 60 of about 5,939 (158)

Upadacitinib versus Tofacitinib in the Management of Ulcerative Colitis: A Systematic Review and Meta-Analysis

Inflammatory Intestinal Diseases
Introduction: Upadacitinib and tofacitinib, oral Janus kinase inhibitors, have demonstrated efficacy and safety in ulcerative colitis (UC) in clinical trials. However, real-world comparative data are limited.
Tareq Alsaleh, Abdul Mohammed, Aimen Farooq, Magda Elamin, Amr Akl, Karim Mohamed Yassin, Ahmed Elnaggar, Jennifer Seminerio   +7 more
doaj   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy

Alimentary Pharmacology &Therapeutics, EarlyView.
The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins, Srinivas Kamath, Rachel H. Davis, Samuel P. Costello, Robert V. Bryant, Alice S. Day, Paul Joyce   +6 more
wiley   +1 more source

Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial

RMD Open
Objective To assess the long-term safety and efficacy of upadacitinib over 5 years in Japanese patients with moderate-to-severe active rheumatoid arthritis and an inadequate response to stable doses of conventional synthetic disease-modifying ...
Tsutomu Takeuchi, Hideto Kameda, Yoshiya Tanaka, Mitsuhiro Kawano, Motohiro Oribe, Kunihiro Yamaoka, Heidi S Camp, Yuko Konishi, Sumi Chonan, Kimitoshi Ikeda   +9 more
doaj   +1 more source

Development of an UPLC-MS/MS Method for the Quantitative Analysis of Upadacitinib in Beagle Dog Plasma and Pharmacokinetics Study

Drug Design, Development and Therapy, 2021
Meng-Jie Wang,1 Yu-Hang Zhao,2 Chen Fan,3 Ying-Jie Wang,3 Xin-Qi Wang,3 Xiang-Jun Qiu,3 Rui-Le Shen1 1Department of Neurology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan ...
Wang MJ, Zhao YH, Fan C, Wang YJ, Wang XQ, Qiu XJ, Shen RL   +6 more
doaj  

Elevated IL‐4 and IL‐13 Expression in Hailey‐Hailey Disease: Evidence for Th2‐Mediated Pathogenesis and Targeted Treatment

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Hailey‐Hailey disease (HHD) is a rare autosomal dominant blistering disorder caused by mutations in the ATP2C1 gene, which impair keratinocyte adhesion through disrupted calcium signaling. While traditionally considered a structural defect, recent studies suggest that Th2‐mediated inflammation may exacerbate disease pathology ...
Simonetta I. Gaumond, Victoria Soto, Beatriz Abdo Abujamra, Franco Rongioletti, John A. McGrath, Ivan Jozic, Paolo Romanelli   +6 more
wiley   +1 more source

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study

Arthritis Research & Therapy
Background In SELECT-AXIS 2, upadacitinib improved the signs and symptoms of active non-radiographic axial spondyloarthritis (nr-axSpA) through 52 weeks versus placebo and was well tolerated.
Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P. Maksymowych, Désirée van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Xenofon Baraliakos, Xianwei Bu, Ivan Lagunes-Galindo, In-Ho Song, Peter Wung, Koji Kato, Anna Shmagel   +13 more
doaj   +1 more source

Phenotypes and clinical outcomes in children with moderate‐to‐severe atopic dermatitis across diverse ancestries: a Spanish multicenter observational study and cluster analysis (AD‐SKINS Project)

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Atopic dermatitis (AD) has a highly variable clinical phenotype and ancestry can contribute to this heterogeneity. This study aims to identify clinical phenotypes of AD in children from diverse ancestry groups, evaluate clinical outcomes and response to treatment, and define phenotypic clusters with potential relevance.
Eugeni Prat‐Colilles, Adrià Plana‐Pla, Asunción Vicente, Eulàlia Baselga, Helena Iznardo, Esther Roé, Miquel Casals‐Andreu, Maria Sin‐Soler, Josep A. Pujol‐Montcusí, Maria del Mar Cordellat‐Martínez, Xavier Soria‐Gili, Maria del Mar Tapias‐Terré, Marta Bertolin‐Colilla, Nidia Planella‐Fontanillas, Laura Marques‐Martín, Mónica Munera‐Campos, Maria Fabregat‐Pratdepadua, Carolina S. Prat‐Torres, Marta Ivars, Luisa F. Montenegro‐Morillo, Isabel Bielsa‐Marsol, Jose‐Manuel Carrascosa‐Carrillo   +21 more
wiley   +1 more source

Erosion Regression in Patients with RA After Upadacitinib-A Pilot Study Using High Resolution Peripheral Quantitative Computed Tomography

Journal of Clinical Rheumatology and Immunology
Background: Janus kinases inhibitor (JAKi) is a potent drug in treating patients with rheumatoid arthritis (RA). However, the effect of JAKi on finite structural changes remained uncertain.
Isaac T Cheng, Ho So, Evelyn H Chow, Qihan Wu, Martin Li, Vivian W Hung, Ling Qin, Chun Kwok Wong, Lai Shan Tam   +8 more
doaj   +1 more source

Cold plasma treatment for oral lichen planus: a retrospective case collection and proposal of a new clinical score

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Oral lichen planus (OLP) is a chronic autoimmune mucosal disease with malignant potential and limited treatment options. This study evaluated the long‐term efficacy and safety of cold atmospheric plasma (CAP) therapy in therapy‐refractory OLP and introduced the novel Lichen Planus Severity Score (LPSS).
Christian Seebauer, Hans‐Robert Metelmann, Mohamed Falougy, Wolfram Kaduk, Lasse Kremer, Georg Daeschlein   +5 more
wiley   +1 more source